GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial ...
WARRINGTON, Pa. and PRINCETON, N.J., June 4, 2019 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates ...
BullFrog AI Holdings has announced a partnership agreement with Eleison Pharmaceuticals to apply its artificial intelligence (AI) solutions to Eleison’s pivotal Phase III trial of pancreatic cancer ...
GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial ...
(RTTNews) - BullFrog AI Holdings, Inc. (BFRG) has entered into a collaboration agreement with Eleison Pharmaceuticals Inc. to optimize clinical trials for glufosfamide, an investigational treatment ...
Eleison Pharmaceuticals (ESLN) has withdrawn its registration for a proposed $40M initial public offering. The oncology drug developer first filed for the IPO in January 2022. Based in New Jersey, ...
BullFrog AI (BFRG) Holdings provided an update on its collaboration with Eleison Pharmaceuticals. To support this collaboration, BullFrog AI developed a new data ingestion module, purpose-built to ...
Validates BullFrog AI’s enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback